Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.
  • Bosdriesz, Evert
  • Ooft, Salo N.
  • Farre, Lourdes
  • McLean, Chelsea
  • Martínez Marti, Alexandre
  • Nadal, Ernest
  • Felip Font, Enriqueta
Càncer; Càncer de pulmó; Farmacoresistència, Cáncer; Cáncer de pulmón; Farmacorresistencia, Cancer; Lung cancer; Drug resistance, Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy., This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer

  • Hergueta-Redondo, Marta
  • Sarrio, David
  • Molina-Crespo, Ángela
  • Vicario, Rocío
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Martínez, Lidia
  • Rojo-Sebastián, Alejandro
  • Serra-Musach, Jordi
  • Mota, Alba
  • Martínez-Ramírez, Ángel
  • Castilla, Maria Ángeles
  • González-Martin, Antonio
  • Pernas, Sonia|||0000-0002-1485-5080
  • Cano, Amparo
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Peg, Vicente|||0000-0002-5203-6166
  • Palacios, José|||0000-0002-6730-5066
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Moreno-Bueno, Gema
Around, 30-40% of HER2-positive breast cancers do not show substantial clinical benefit from the targeted therapy and, thus, the mechanisms underlying resistance remain partially unknown. Interestingly, ERBB2 is frequently co-amplified and co-expressed with neighbour genes that may play a relevant role in this cancer subtype. Here, using an in silico analysis of data from 2,096 breast tumours, we reveal a significant correlation between Gasdermin B (GSDMB) gene (located 175 kilo bases distal from ERBB2) expression and the pathological and clinical parameters of poor prognosis in HER2-positive breast cancer. Next, the analysis of three independent cohorts (totalizing 286 tumours) showed that approximately 65% of the HER2-positive cases have GSDMB gene amplification and protein over-expression. Moreover, GSDMB expression was also linked to poor therapeutic responses in terms of lower relapse free survival and pathologic complete response as well as positive lymph node status and the development of distant metastasis under neoadjuvant and adjuvant treatment settings, respectively. Importantly, GSDMB expression promotes survival to trastuzumab in different HER2-positive breast carcinoma cells, and is associated with trastuzumab resistance phenotype in vivo in Patient Derived Xenografts. In summary, our data identifies the ERBB2 co-amplified and co-expressed gene GSDMB as a critical determinant of poor prognosis and therapeutic response in HER2-positive breast cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cancer network activity associated with therapeutic response and synergism

  • Serra-Musach, Jordi
  • Mateo, Francesca|||0000-0002-2342-7010
  • Capdevila Busquets, Eva
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Zhang, Xiaohu
  • Guha, Raj
  • Thomas, Craig J.
  • Grueso, Judit|||0000-0003-1093-7940
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Jaeger, Samira
  • Heyn, Holger|||0000-0002-3276-1889
  • Vizoso, Miguel
  • Pérez Montero, Hector|||0000-0002-9756-5088
  • Cordero, Alex
  • González Suarez, Eva
  • Esteller, M.|||0000-0003-4490-6093
  • Moreno-Bueno, Gema
  • Tjärnberg, Andreas
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Serra, Violeta|||0000-0001-6620-1065
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Benson, Mikael
  • Gustafsson, Mika
  • Ferrer Massot, Marc|||0000-0003-0046-1301
  • Aloy, Patrick|||0000-0002-3557-0236
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer cell activity may support a comprehensive mechanistic understanding of therapy efficacy. We reasoned that network analysis of omic data could help to achieve this goal. A measure of "cancer network activity" (CNA) was implemented based on a previously defined network feature of communicability. The network nodes and edges corresponded to human proteins and experimentally identified interactions, respectively. The edges were weighted proportionally to the expression of the genes encoding for the corresponding proteins and relative to the number of direct interactors. The gene expression data corresponded to the basal conditions of 595 human cancer cell lines. Therapeutic responses corresponded to the impairment of cell viability measured by the half maximal inhibitory concentration (IC) of 130 drugs approved or under clinical development. Gene ontology, signaling pathway, and transcription factor-binding annotations were taken from public repositories. Predicted synergies were assessed by determining the viability of four breast cancer cell lines and by applying two different analytical methods. The effects of drug classes were associated with CNAs formed by different cell lines. CNAs also differentiate target families and effector pathways. Proteins that occupy a central position in the network largely contribute to CNA. Known key cancer-associated biological processes, signaling pathways, and master regulators also contribute to CNA. Moreover, the major cancer drivers frequently mediate CNA and therapeutic differences. Cell-based assays centered on these differences and using uncorrelated drug effects reveals novel synergistic combinations for the treatment of breast cancer dependent on PI3K-mTOR signaling. Cancer therapeutic responses can be predicted on the basis of a systems-level analysis of molecular interactions and gene expression. Fundamental cancer processes, pathways, and drivers contribute to this feature, which can also be exploited to predict precise synergistic drug combinations. The online version of this article (doi:10.1186/s13073-016-0340-x) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.|||0000-0002-0549-8835
  • Nadal, Ernest|||0000-0002-9674-5554
  • Bosdriesz, Evert|||0000-0002-8788-9548
  • Ooft, Salo N.|||0000-0002-3990-3376
  • Farré, Lourdes|||0000-0002-3168-1940
  • McLean, Chelsea|||0000-0002-3548-3482
  • Klarenbeek, Sjoerd
  • Jurgens, Anouk
  • Hagen, Hannes
  • Wang, Liqin
  • Felip, Enriqueta|||0000-0002-7620-0098
  • Martinez-Marti, Alex|||0000-0002-6714-9526
  • Vidal, August|||0000-0001-5727-2099
  • Voest, Emile|||0000-0001-8249-9586
  • Wessels, Lodewyk F. A.
  • van Tellingen, Olaf|||0000-0002-1037-6269
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Bernards, Rene|||0000-0001-8677-3423
Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy. A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Disease networks identify specific conditions and pleiotropy influencing multimorbidity in the general population

  • Amell, A.
  • Roso-Llorach, Albert|||0000-0002-9264-0405
  • Palomero, L.
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Galván-Femenía, Iván|||0000-0002-6124-3730
  • Serra-Musach, J.
  • Comellas, Francesc|||0000-0003-4523-0240
  • de Cid, Rafael|||0000-0003-3579-6777
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Violán, Concepció|||0000-0003-3309-5360
Multimorbidity is an emerging topic in public health policy because of its increasing prevalence and socio-economic impact. However, the age- and gender-dependent trends of disease associations at fine resolution, and the underlying genetic factors, remain incompletely understood. Here, by analyzing disease networks from electronic medical records of primary health care, we identify key conditions and shared genetic factors influencing multimorbidity. Three types of diseases are outlined: "central", which include chronic and non-chronic conditions, have higher cumulative risks of disease associations; "community roots" have lower cumulative risks, but inform on continuing clustered disease associations with age; and "seeds of bursts", which most are chronic, reveal outbreaks of disease associations leading to multimorbidity. The diseases with a major impact on multimorbidity are caused by genes that occupy central positions in the network of human disease genes. Alteration of lipid metabolism connects breast cancer, diabetic neuropathy and nutritional anemia. Evaluation of key disease associations by a genome-wide association study identifies shared genetic factors and further supports causal commonalities between nervous system diseases and nutritional anemias. This study also reveals many shared genetic signals with other diseases. Collectively, our results depict novel population-based multimorbidity patterns, identify key diseases within them, and highlight pleiotropy influencing multimorbidity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus

  • Zeng, Chenjie
  • Guo, Xingyi
  • Long, Jirong
  • Kuchenbaecker, Karoline B.
  • Droit, Arnaud
  • Michailidou, Kyriaki
  • Ghoussaini, Maya
  • Kar, Siddhartha
  • Freeman, Adam
  • Hopper, John L.
  • Milne, Roger L.|||0000-0001-5764-7268
  • Bolla, Manjeet K.|||0000-0002-4351-9326
  • Wang, Qin
  • Dennis, Joe|||0000-0003-4591-1214
  • Agata, Simona
  • Ahmed, Shahana
  • Aittomäki, Kristiina
  • Andrulis, Irene L.|||0000-0002-4226-6435
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arason, Adalgeir|||0000-0003-0480-886X
  • Arndt, Volker|||0000-0001-9320-8684
  • Arun, Banu K.
  • Arver, Brita
  • Bacot, Francois
  • Barrowdale, Daniel|||0000-0003-1661-3939
  • Baynes, Caroline
  • Beeghly-Fadiel, Alicia|||0000-0001-9913-732X
  • Benitez, Javier|||0000-0002-0923-7202
  • Bermisheva, Marina
  • Blomqvist, Carl
  • Blot, William
  • Bogdanova, Natalia V.
  • Bojesen, Stig E.
  • Bonanni, Bernardo|||0000-0003-3589-2128
  • Borresen-Dale, Anne-Lise
  • Brand, Judith S.
  • Brauch, Hiltrud|||0000-0001-7531-2736
  • Brennan, Paul
  • Brenner, Hermann
  • Broeks, Annegien
  • Brüning, Thomas
  • Burwinkel, Barbara
  • Buys, Saundra|||0000-0003-4120-5697
  • Cai, Qiuyin
  • Caldes, Trinidad
  • Campbell, Ian|||0000-0002-7773-4155
  • Carpenter, Jane
  • Chang-Claude, Jenny
  • Choi, Ji-Yeob
  • Claes, Kathleen|||0000-0003-0841-7372
  • Clarke, Christine L.
  • Cox, Angela
  • Cross, Simon S.
  • Czene, Kamila
  • Daly, Mary B.
  • Hoya, Miguel de la|||0000-0002-8113-1410
  • De Leeneer, Kim
  • Devilee, Peter|||0000-0002-8023-2009
  • Diez, Orland|||0000-0001-7339-0570
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Doody, Michele
  • Dorfling, Cecilia M.
  • Dörk, Thilo|||0000-0002-9458-0282
  • dos-Santos-Silva, Isabel
  • Dumont, Martine
  • Dwek, Miriam
  • Dworniczak, Bernd
  • Egan, Kathleen
  • Eilber, Ursula
  • Einbeigi, Zakaria
  • Ejlertsen, Bent
  • Ellis, Steve
  • Frost, Debra
  • Lalloo, Fiona
  • Fasching, Peter A.
  • Figueroa, Jonine
  • Flyger, Henrik
  • Friedlander, Michael|||0000-0003-3090-795X
  • Friedman, Eitan|||0000-0002-6745-1733
  • Gambino, Gaetana
  • Gao, Yu-Tang
  • Garber, Judy
  • García-Closas, Montserrat
  • Gehrig, Andrea
  • Damiola, Francesca
  • Lesueur, Fabienne|||0000-0001-7404-4549
  • Mazoyer, Sylvie
  • Stoppa-Lyonnet, Dominique
  • Giles, Graham G.
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Goldgar, David E.
  • González-Neira, Anna
  • Greene, Mark H.|||0000-0003-1852-9239
  • Guénel, Pascal
  • Haeberle, Lothar
  • Haiman, Christopher A.
  • Hallberg, Emily
  • Hamann, Ute|||0000-0001-6705-7624
  • Hansen, Thomas V. O.
  • Hart, Steven
  • Hartikainen, Jaana M.
  • Hartman, Mikael
  • Hassan, Norhashimah
  • Healey, Sue
  • Hogervorst, Frans B. L.
  • Verhoef, Senno
  • Hendricks, Carolyn B.
  • Hillemanns, Peter
  • Hollestelle, Antoinette
  • Hulick, Peter J.
  • Hunter, David J.
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine|||0000-0002-9646-1260
  • Ito, Hidemi
  • Jakubowska, Anna|||0000-0002-5650-0501
  • Janavicius, Ramunas
  • Jaworska-Bieniek, Katarzyna
  • Jensen, Uffe Birk
  • John, Esther M.
  • Joly Beauparlant, Charles
  • Jones, Michael
  • Kabisch, Maria
  • Kang, Daehee
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Kauppila, Saila
  • Kerin, Michael J.
  • Khan, Sofia
  • Khusnutdinova, Elza
  • Knight, Julia A.
  • Konstantopoulou, Irene|||0000-0002-0470-0309
  • Kraft, Peter
  • Kwong, Ava
  • Laitman, Yael
  • Lambrechts, Diether
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Le Marchand, Loic
  • Lee, Chuen Neng
  • Lee, Min Hyuk
  • Lester, Jenny
  • Li, Jingmei
  • Liljegren, Annelie
  • Lindblom, Annika
  • Lophatananon, Artitaya
  • Lubinski, Jan|||0000-0003-2931-3003
  • Mai, Phuong L.
  • Mannermaa, Arto
  • Manoukian, Siranoush
  • Margolin, Sara
  • Marme, Frederik
  • Matsuo, Keitaro
  • McGuffog, Lesley|||0000-0003-1237-0546
  • Meindl, Alfons
  • Menegaux, Florence
  • Montagna, Marco
  • Muir, Kenneth
  • Mulligan, Anna Marie
  • Nathanson, Katherine L.|||0000-0002-6740-0901
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Nevanlinna, Heli|||0000-0002-0916-2976
  • Newcomb, Polly A.
  • Nord, Silje
  • Nussbaum, Robert L.|||0000-0003-3445-8880
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.|||0000-0002-9936-1599
  • Olswold, Curtis
  • Osorio, Ana|||0000-0001-8124-3984
  • Papi, Laura
  • Park-Simon, Tjoung-Won
  • Paulsson-Karlsson, Ylva
  • Peeters, Stephanie
  • Peissel, Bernard|||0000-0001-9233-3571
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Peto, Julian|||0000-0002-1685-8912
  • Pfeiler, Georg
  • Phelan, Catherine M.
  • Presneau, Nadege
  • Radice, Paolo|||0000-0001-6298-4111
  • Rahman, Nazneen
  • Ramus, Susan J.|||0000-0003-0005-7798
  • Rashid, Muhammad Usman
  • Rennert, Gad|||0000-0002-8512-068X
  • Rhiem, Kerstin
  • Rudolph, Anja
  • Salani, Ritu
  • Sangrajrang, Suleeporn
  • Sawyer, Elinor J.
  • Schmidt, Marjanka K.|||0000-0002-2228-429X
  • Schmutzler, Rita K.
  • Schoemaker, Minouk J.
  • Schürmann, Peter
  • Seynaeve, Caroline
  • Shen, Chen-Yang
  • Shrubsole, Martha J.
  • Shu, Xiao-Ou
  • Sigurdson, Alice
  • Singer, Christian F.
  • Slager, Susan|||0000-0002-5173-4712
  • Soucy, Penny
  • Southey, Melissa C.|||0000-0002-6313-9005
  • Steinemann, Doris|||0000-0001-8797-0816
  • Swerdlow, Anthony
  • Szabo, Csilla I.
  • Tchatchou, Sandrine
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Teo, Soo|||0000-0002-0444-590X
  • Terry, Mary Beth
  • Tessier, Daniel C.
  • Teule, Alex|||0000-0003-0028-7200
  • Thomassen, Mads
  • Tihomirova, Laima
  • Tischkowitz, Marc
  • Toland, Amanda Ewart|||0000-0002-0271-1792
  • Tung, Nadine
  • Turnbull, Clare
  • van den Ouweland, Ans M. W.
  • van Rensburg, Elizabeth J.|||0000-0003-2077-230X
  • ven den Berg, David
  • Vijai, Joseph
  • Wang-Gohrke, Shan
  • Weitzel, Jeffrey N.
  • Whittemore, Alice S.
  • Winqvist, Robert
  • Wong, Tien Y.
  • Wu, Anna H.
  • Yannoukakos, Drakoulis
  • Yu, Jyh-Cherng
  • Pharoah, Paul D.P.|||0000-0001-8494-732X
  • Hall, Per
  • Chenevix-Trench, Georgia
  • Dunning, Alison M.
  • Simard, Jacques|||0000-0001-6906-3390
  • Couch, Fergus J.
  • Antoniou, Antonis C.
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Zheng, Wei|||0000-0003-1226-070X
Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk. We performed a fine-scale mapping study of a 700 kb region including 441 genotyped and more than 1300 imputed genetic variants in 48,155 cases and 43,612 controls of European descent, 6269 cases and 6624 controls of East Asian descent and 1116 cases and 932 controls of African descent in the Breast Cancer Association Consortium (BCAC; ), and in 15,252 BRCA1 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Stepwise regression analyses were performed to identify independent association signals. Data from the Encyclopedia of DNA Elements project (ENCODE) and the Cancer Genome Atlas (TCGA) were used for functional annotation. Analysis of data from European descendants found evidence for four independent association signals at 12p11, represented by rs7297051 (odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.06-1.12; P = 3 × 10 -9), rs805510 (OR = 1.08, 95 % CI = 1.04-1.12, P = 2 × 10 -5), and rs1871152 (OR = 1.04, 95 % CI = 1.02-1.06; P = 2 × 10 -4) identified in the general populations, and rs113824616 (P = 7 × 10 -5) identified in the meta-analysis of BCAC ER-negative cases and BRCA1 mutation carriers. SNPs rs7297051, rs805510 and rs113824616 were also associated with breast cancer risk at P < 0.05 in East Asians, but none of the associations were statistically significant in African descendants. Multiple candidate functional variants are located in putative enhancer sequences. Chromatin interaction data suggested that PTHLH was the likely target gene of these enhancers. Of the six variants with the strongest evidence of potential functionality, rs11049453 was statistically significantly associated with the expression of PTHLH and its nearby gene CCDC91 at P < 0.05. This study identified four independent association signals at 12p11 and revealed potentially functional variants, providing additional insights into the underlying biological mechanism(s) for the association observed between variants at 12p11 and breast cancer risk. The online version of this article (doi:10.1186/s13058-016-0718-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade

  • Romero, Octavio A.|||0000-0003-0229-6530
  • Vilarrubi, Andrea|||0000-0002-2930-3246
  • Alburquerque-Béjar, Juan Jos|||0000-0002-9022-124X
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Andrades, Álvaro
  • Trastulli, Deborah|||0000-0003-2407-3290
  • Pros, Eva|||0000-0002-2366-7866
  • Setien, Fernando|||0000-0002-4061-4635
  • Verdura, Sara|||0000-0001-8980-0423
  • Farré, Lourdes|||0000-0002-3168-1940
  • Martín-Tejera, Juan F.
  • Llabata, Paula|||0000-0001-7733-6475
  • Oaknin, Ana|||0000-0002-3592-7194
  • Saigí, Maria|||0000-0001-5815-5388
  • Piulats, Josep M.|||0000-0002-3606-1724
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Medina, Pedro P.
  • Vidal, August|||0000-0001-5727-2099
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
Despite the genetic inactivation of SMARCA4, a core component of the SWI/SNF-complex commonly found in cancer, there are no therapies that effectively target SMARCA4-deficient tumours. Here, we show that, unlike the cells with activated MYC oncogene, cells with SMARCA4 inactivation are refractory to the histone deacetylase inhibitor, SAHA, leading to the aberrant accumulation of H3K27me3. SMARCA4-mutant cells also show an impaired transactivation and significantly reduced levels of the histone demethylases KDM6A/UTX and KDM6B/JMJD3, and a strong dependency on these histone demethylases, so that its inhibition compromises cell viability. Administering the KDM6 inhibitor GSK-J4 to mice orthotopically implanted with SMARCA4-mutant lung cancer cells or primary small cell carcinoma of the ovary, hypercalcaemic type (SCCOHT), had strong anti-tumour effects. In this work we highlight the vulnerability of KDM6 inhibitors as a characteristic that could be exploited for treating SMARCA4-mutant cancer patients.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours

  • Fernandes Neto, João M.
  • Bosdriesz, Evert
  • Ooft, Salo N.
  • Farre, Lourdes
  • McLean, Chelsea
  • Martínez Marti, Alexandre
  • Nadal, Ernest
  • Felip Font, Enriqueta
Càncer; Càncer de pulmó; Farmacoresistència, Cáncer; Cáncer de pulmón; Farmacorresistencia, Cancer; Lung cancer; Drug resistance, Resistance to targeted cancer drugs is thought to result from selective pressure exerted by a high drug dose. Partial inhibition of multiple components in the same oncogenic signalling pathway may add up to complete pathway inhibition, while decreasing the selective pressure on each component to acquire a resistance mutation. We report here testing of this Multiple Low Dose (MLD) therapy model in EGFR mutant NSCLC. We show that as little as 20% of the individual effective drug doses is sufficient to completely block MAPK signalling and proliferation when used in 3D (RAF + MEK + ERK) or 4D (EGFR + RAF + MEK + ERK) inhibitor combinations. Importantly, EGFR mutant NSCLC cells treated with MLD therapy do not develop resistance. Using several animal models, we find durable responses to MLD therapy without associated toxicity. Our data support the notion that MLD therapy could deliver clinical benefit, even for those having acquired resistance to third generation EGFR inhibitor therapy., This work was supported by a grant from the Dutch Cancer Society through the Oncode Institute. Al.V. was supported by the Fondo de Investigaciones Sanitarias, FIS (PI16-01898, and by the Spanish Association Against Cancer, AECC (CGB14142035THOM) and Ideas Semilla project (IDEAS098VILL-IDEAS16) and Generalitat de Catalunya (2014SGR364). L.F. received a European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie, grant agreement number 799850. E.N. was funded by Instituto Carlos III through the project PI18/00920. We thank CERCA Program/Generalitat de Catalunya for their institutional support and grant 2017SGR448.